Načítá se...
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Primary liver cancer is one of the commonest causes of death. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers. For patients with unresectable or metastatic HCC, conventional chemotherapy is of limited or no benefit. Sorafenib is the only systemic treatment to demonstrate a s...
Uloženo v:
| Vydáno v: | World J Hepatol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4404384/ https://ncbi.nlm.nih.gov/pubmed/25914779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v7.i5.787 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|